Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis.

Autor:	Kourek C; Clinical Ergospirometry, Exercise and Rehabilitation Laboratory, 1 Critical Care Medicine Department, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens 10676, Greece., Briasoulis A; Department of Clinical Therapeutics, Alexandra Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece., Magouliotis DE; Department of Cardiothoracic Surgery, University of Thessaly, Larissa Biopolis, Larissa 41110, Greece., Georgoulias P; Department of Nuclear Medicine, University Hospital of Larissa, Larissa 41110, Greece., Giamouzis G; Department of Cardiology, School of Medicine, University Hospital of Larissa, Larissa 41110, Greece., Triposkiadis F; Department of Cardiology, School of Medicine, University Hospital of Larissa, Larissa 41110, Greece., Skoularigis J; Department of Cardiology, School of Medicine, University Hospital of Larissa, Larissa 41110, Greece., Xanthopoulos A; Department of Cardiology, School of Medicine, University Hospital of Larissa, Larissa 41110, Greece. andrewvxanth@gmail.com.
Jazyk:	angličtina
Zdroj:	World journal of cardiology [World J Cardiol] 2024 Jul 26; Vol. 16 (7), pp. 370-379.
DOI:	10.4330/wjc.v16.i7.370
Abstrakt:	Cardiac amyloidosis is a progressive disease characterized by the buildup of amyloid fibrils in the extracellular space of the heart. It is divided in 2 main types, immunoglobulin light chain amyloidosis and transthyretin amyloidosis (ATTR), and ATTR amyloidosis is further divided in 2 subtypes, non-hereditary wild type ATTR and hereditary mutant variant amyloidosis. Incidence and prevalence of ATTR cardiac amyloidosis is increasing over the last years due to the improvements in diagnostic methods. Survival rates are improving due to the development of novel therapeutic strategies. Tafamidis is the only disease-modifying approved therapy in ATTR amyloidosis so far. However, the most recent advances in medical therapies have added more options with the potential to become part of the therapeutic armamentarium of the disease. Agents including acoramidis, eplontersen, vutrisiran, patisiran and anti-monoclonal antibody NI006 are being investigated on cardiac function in large, multicenter controlled trials which are expected to be completed within the next 2-3 years, providing promising results in patients with ATTR cardiac amyloidosis. However, further and ongoing research is required in order to improve diagnostic methods that could provide an early diagnosis, as well as survival and quality of life of these patients. Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu